Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Down 1.1 %

NASDAQ:EVGN opened at $1.73 on Monday. The firm’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $4.61. Evogene has a fifty-two week low of $1.70 and a fifty-two week high of $10.40. The stock has a market cap of $9.29 million, a PE ratio of -0.44 and a beta of 1.43.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The company had revenue of $0.91 million during the quarter.

Institutional Investors Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets lifted its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.